CA2226392A1 - Intranasal vaccination against gastrointestinal disease - Google Patents
Intranasal vaccination against gastrointestinal disease Download PDFInfo
- Publication number
- CA2226392A1 CA2226392A1 CA002226392A CA2226392A CA2226392A1 CA 2226392 A1 CA2226392 A1 CA 2226392A1 CA 002226392 A CA002226392 A CA 002226392A CA 2226392 A CA2226392 A CA 2226392A CA 2226392 A1 CA2226392 A1 CA 2226392A1
- Authority
- CA
- Canada
- Prior art keywords
- toxin
- composition
- difficile
- toxoid
- mucosal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002255 vaccination Methods 0.000 title abstract description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 title description 3
- 208000010643 digestive system disease Diseases 0.000 title description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 title description 3
- 241000193163 Clostridioides difficile Species 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 53
- 244000052769 pathogen Species 0.000 claims abstract description 21
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 241000193403 Clostridium Species 0.000 claims abstract description 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 78
- 101710182532 Toxin a Proteins 0.000 claims description 78
- 239000003053 toxin Substances 0.000 claims description 55
- 231100000765 toxin Toxicity 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 206010012735 Diarrhoea Diseases 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 17
- 230000001717 pathogenic effect Effects 0.000 claims description 15
- 230000016379 mucosal immune response Effects 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 108700022831 Clostridium difficile toxB Proteins 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract description 32
- 230000003053 immunization Effects 0.000 abstract description 21
- 238000002649 immunization Methods 0.000 abstract description 21
- 238000007920 subcutaneous administration Methods 0.000 abstract description 18
- 230000001681 protective effect Effects 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 108700012359 toxins Proteins 0.000 description 54
- 241000699800 Cricetinae Species 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 44
- 101710182223 Toxin B Proteins 0.000 description 38
- 210000002966 serum Anatomy 0.000 description 31
- 229960005486 vaccine Drugs 0.000 description 30
- 230000004044 response Effects 0.000 description 28
- 239000002671 adjuvant Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 210000003608 fece Anatomy 0.000 description 16
- 102000009016 Cholera Toxin Human genes 0.000 description 15
- 108010049048 Cholera Toxin Proteins 0.000 description 15
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 10
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 10
- 229960002227 clindamycin Drugs 0.000 description 10
- 231100000174 enterotoxicity Toxicity 0.000 description 10
- 230000004520 agglutination Effects 0.000 description 9
- 230000001147 anti-toxic effect Effects 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 208000034598 Caecitis Diseases 0.000 description 8
- 208000004387 Typhlitis Diseases 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000001820 anti-cytotoxin effect Effects 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 210000003756 cervix mucus Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000002619 cytotoxin Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 229940031572 toxoid vaccine Drugs 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 241001112696 Clostridia Species 0.000 description 3
- 241000186581 Clostridium novyi Species 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 241000193465 Paeniclostridium sordellii Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002242 enterotoxic effect Effects 0.000 description 3
- 239000000147 enterotoxin Substances 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011553 hamster model Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000589876 Campylobacter Species 0.000 description 2
- 241001248433 Campylobacteraceae Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000590017 Helicobacter felis Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000947860 Pasteurellales Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000589157 Rhizobiales Species 0.000 description 2
- 108010073443 Ribi adjuvant Proteins 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 244000000036 gastrointestinal pathogen Species 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000364021 Tulsa Species 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000006328 chemical modification of amino acids Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49922995A | 1995-07-07 | 1995-07-07 | |
| US08/499,229 | 1995-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2226392A1 true CA2226392A1 (en) | 1997-01-30 |
Family
ID=23984386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002226392A Abandoned CA2226392A1 (en) | 1995-07-07 | 1996-06-26 | Intranasal vaccination against gastrointestinal disease |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0877623A1 (en:Method) |
| JP (1) | JPH11510793A (en:Method) |
| CN (1) | CN1195993A (en:Method) |
| AU (1) | AU722653B2 (en:Method) |
| CA (1) | CA2226392A1 (en:Method) |
| NZ (1) | NZ312876A (en:Method) |
| WO (1) | WO1997002835A1 (en:Method) |
| ZA (1) | ZA965737B (en:Method) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6585975B1 (en) * | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
| KR100627635B1 (ko) * | 1999-11-01 | 2006-09-25 | 뮤코 박스 홀딩 비.브이. | 가축에서 유선 분비 항체를 제조하는 방법 |
| US7074454B1 (en) | 1999-11-01 | 2006-07-11 | Mucovax Holding B.V. | Production of mammary secretion antibodies in farm animals |
| US6974573B2 (en) | 1999-11-01 | 2005-12-13 | Mucovax Holdings, B.V. | Antibody production in farm animals |
| GB0029919D0 (en) * | 2000-12-07 | 2001-01-24 | Chiron Spa | Helicobacter pylori prime & boost vaccination |
| EP2161035B1 (en) * | 2007-05-28 | 2019-08-21 | Daiichi Sankyo Company, Limited | Bordetella parapertussis-containing whole-cell vaccine composition |
| EP2198007B1 (en) * | 2007-09-14 | 2017-10-25 | Sanofi Pasteur Biologics, LLC | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| US20110243991A1 (en) * | 2008-12-03 | 2011-10-06 | Boehringer Ingelheim Vetmedica Gmbh | Process for production of vaccines |
| JP2013512916A (ja) * | 2009-12-02 | 2013-04-18 | タフツ ユニバーシティー | 免疫原としてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅの無毒の組換えホロトキシン |
| ES2969952T3 (es) | 2011-04-22 | 2024-05-23 | Wyeth Llc | Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos |
| US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141970A (en) * | 1975-05-07 | 1979-02-27 | Internationale Octrooimaatschappij "Octropa" B.V. | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections |
| US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
| US4944942A (en) * | 1987-08-27 | 1990-07-31 | Mobay Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic material |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| GB9209118D0 (en) * | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
| AU4773293A (en) * | 1992-07-16 | 1994-02-14 | Oxford University | Multiple particulate antigen delivery system |
-
1996
- 1996-06-26 EP EP96924312A patent/EP0877623A1/en not_active Withdrawn
- 1996-06-26 JP JP9505849A patent/JPH11510793A/ja active Pending
- 1996-06-26 AU AU64799/96A patent/AU722653B2/en not_active Ceased
- 1996-06-26 CN CN96196763A patent/CN1195993A/zh active Pending
- 1996-06-26 WO PCT/US1996/010987 patent/WO1997002835A1/en not_active Ceased
- 1996-06-26 NZ NZ312876A patent/NZ312876A/en unknown
- 1996-06-26 CA CA002226392A patent/CA2226392A1/en not_active Abandoned
- 1996-07-05 ZA ZA965737A patent/ZA965737B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA965737B (en) | 1997-05-13 |
| NZ312876A (en) | 2000-06-23 |
| WO1997002835A1 (en) | 1997-01-30 |
| AU6479996A (en) | 1997-02-10 |
| JPH11510793A (ja) | 1999-09-21 |
| EP0877623A1 (en) | 1998-11-18 |
| CN1195993A (zh) | 1998-10-14 |
| EP0877623A4 (en:Method) | 1998-11-18 |
| AU722653B2 (en) | 2000-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Torres et al. | Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters | |
| Allaoui-Attarki et al. | Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-glycolide) microspheres | |
| Acheson et al. | Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR | |
| FI120137B (fi) | Mutanttienterotoksiini, joka on tehokas ei-toksisena suun kautta annettavana adjuvanttina | |
| AU722653B2 (en) | Intranasal vaccination against gastrointestinal disease | |
| US8481057B2 (en) | Chlamydial antigens | |
| US5919463A (en) | Clostridium difficle toxins as mucosal adjuvants | |
| EP0578293B1 (en) | E-coli P-fimbrine as immunogenic carrier system against GnRH | |
| CN105377879A (zh) | 针对衣原体属物种的疫苗 | |
| EP0837692B1 (en) | Clostridium difficile toxins and toxoids as mucosal adjuvants | |
| US9061002B2 (en) | Use of flagellins from the genus Marinobacter as vaccination adjuvants | |
| US7271251B2 (en) | Helicobacter pylori adhesin binding group antigen | |
| Blake et al. | Vaccines for gonorrhea: where are we on the curve? | |
| JP4236215B2 (ja) | 非型性のヘモフイルス インフルエンザ（Ｈａｅｍｏｐｈｉｌｕｓ ｉｎｆｌｕｅｎｚａｅ）株用のワクチンとしての精製非型性ヘモフイルス インフルエンザＰ５蛋白質 | |
| US9119803B2 (en) | Carious tooth vaccine and preparation method | |
| BG61683B1 (bg) | Получаване и използване на убити с формалин организми от видае. coli, експресиращи антиген на колонийобразуващия фактор, заваксиниране срещу чревни инфекции/диарии, причинени отентеротоксични бактерии на e. coli у хората | |
| US6036953A (en) | Heterologous antigens in live cell V. cholerae strains | |
| WO1998023763A9 (en) | Heterologous antigens in live cell v. cholerae strains | |
| Peterson et al. | The effect of orientation within a chimeric peptide on the immunogenicity of Chlamydia trachomatis epitopes | |
| US7094391B1 (en) | Compositions and methods for administering Borrelia burgdorferi antigens | |
| US7049423B2 (en) | Use of the RTX secretion system to achieve heterologous polypeptide secretion by Vibrio cholerae | |
| WO2002079240A2 (en) | Intimins for the prevention or treatment of infections: i | |
| US20020034515A1 (en) | Proteus mirabilis-based vaccine | |
| Producing | Protective Immunity to Shiga-LikeToxin-I following Oral Immunization with Shiga-Like |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |